Genentech BioOncology Co-pay Card Program
Helping you connect to your treatment.
At Genentech, we are committed to helping patients access the treatment they need.
That's why we offer the Genentech BioOncology Co-pay Card. If you are eligible, this card can help lower your out-of-pocket costs like co-payments, co-insurance, or deductibles for your Genentech cancer therapy. Out-of-pocket costs are the part of your treatment that your healthcare plan requires you to pay.
*If you are part of the Genentech® Access to Care Foundation, you are not eligible for the Genentech BioOncology Co-pay Card.
†Massachusetts and Vermont state laws do not allow programs like this.
Answer the questions below to see if you are eligible.*
| Am I eligible? | Yes | No |
What if I am not eligible?
If you answered "no" to any of the questions above but need help paying for your treatment, we can still help you by referring you to an independent nonprofit organization (INO)‡ for financial assistance. If you do not have insurance, you may be able to get free treatment through the Genentech® Access to Care Foundation (GATCF).
Call a Tarceva Access Solutions® Specialist at 1 (888) 249-4918 from 6AM-5PM PST, Monday through Friday, or visit TarcevaAccessSolutions.com to find out more.
‡We cannot guarantee you will get help from an INO. These INOs each have their own rules, including financial rules. Genentech does not influence or control these INOs. But Tarceva Access Solutions can help you. We can refer you to an appropriate INO. We can also help with the application process.
How can this card help me?
Your out-of-pocket costs can add up fast. That's why we offer assistance to patients who have trouble paying for their treatment.
§If your yearly household income is >$100,000, your card limit is $1,500 per year.
You are only required to provide a verbal statement to verify your income at the time of enrollment, but you may have to provide financial documentation at a later date.
How do I enroll?
Enrolling in the Genentech BioOncology Co-pay Card Program is a simple 2-step process.
Terms and conditions
Use of the card does not obligate you to use or continue using any specific product or provider. If you have any questions regarding your eligibility or benefits, or if you wish to no longer be part of the program, contact Genentech BioOncology Co-pay Card at 1 (855) MYCOPAY
(1-855-692-6729).
You may receive additional program information about the Genentech BioOncology Co-pay Card once you are enrolled. Tarceva Access Solutions can also activate this card for you.
No person or entity may seek reimbursement from any third-party payer for any amount provided using the card program. Use of this card must be consistent with all relevant health insurance requirements and payer agreements. Participating patients and pharmacies are obligated to inform third-party payers about this card as provided for under the applicable insurance or as otherwise required by contract or law. Genentech USA, Inc. reserves the right to deny payment under the card to anyone deemed ineligible in accordance with the stated program criteria.
Indications and Usage for Advanced Non-Small Cell Lung Cancer Patients
- Tarceva is prescribed for patients with advanced-stage non-small cell lung cancer (NSCLC) whose cancer has not spread or grown after initial treatment with certain types of chemotherapy.
- Tarceva is prescribed for patients with advanced-stage non-small cell lung cancer (NSCLC) whose cancer has spread or grown after receiving at least 1 chemotherapy regimen.
- Tarceva is not meant to be used at the same time as certain types of chemotherapy for NSCLC.
Indications and Usage for Advanced Pancreatic Cancer Patients
- Tarceva in combination with gemcitabine is prescribed for patients with advanced-stage pancreatic cancer whose cancer has spread, grown, or cannot be surgically removed, and who have not received previous chemotherapy.
Important Safety Information
Possible effects on the lungs
There have been reports of serious adverse events involving the lungs in a small number of patients taking Tarceva. These events have included death in some patients. The medical name for these types of events is interstitial (in-tur-STISH-ul) lung disease-like events (or ILD-like events).
Possible effects on liver and kidney
Liver and/or kidney problems (including deaths) have been reported in some patients taking Tarceva. Let your healthcare provider (HCP) know if you have a history of liver or kidney disease.
Possible effects on the stomach and intestines
Some patients taking Tarceva have developed a hole in the lining of their stomach or intestines. It may happen more in patients who are taking certain other medicines or who have certain stomach or intestinal diseases.
Possible effects on the skin
Some patients taking Tarceva have developed serious skin conditions. Some patients have died from these conditions.
Possible effects on the veins and heart
Patients taking Tarceva plus gemcitabine were more likely to experience bleeding and clotting problems such as heart attack or stroke.
Possible effects on the eye
Some patients taking Tarceva have developed eye irritation and damage to the cornea. The cornea is the clear part of the eyeball that covers the colored part of the eye and the pupil. Other eye problems such as abnormal eyelash growth, dry eyes, or changes in eyesight have also been reported.
Patients should tell their HCP about eye problems that get worse, including eye pain.
Tarceva and pregnancy and breast-feeding
Women should not become pregnant while on treatment with Tarceva. If you are already pregnant or become pregnant while taking Tarceva, you should talk with your HCP about the benefits and risks of continuing to take Tarceva.
DO NOT breast-feed while receiving treatment with Tarceva.
When to call your HCP
Call your HCP right away if you have these signs or symptoms:
- New or worsening skin rash
- Serious or ongoing diarrhea, nausea, loss of appetite, or vomiting
- New or worsening shortness of breath or cough
- Eye irritation
Before you start taking Tarceva
Some patients taking Tarceva have experienced difficulty with blood clotting, and bleeding events, including gastrointestinal and non-gastrointestinal bleeding. Patients taking blood thinners (Coumadin®, warfarin or other coumarin-derivatives) should be monitored regularly.
Taking other medicines and herbal supplements with Tarceva
Certain medicines and herbal supplements can affect how Tarceva works in the body. It is important that you tell your HCP about all of the medicines and herbal supplements you are taking. DO NOT start taking any new medicines or herbal supplements before talking with your HCP. Tarceva may also affect other medications you are taking.
In addition, grapefruit and grapefruit juice have an effect on how Tarceva works. DO NOT eat grapefruit or drink grapefruit juice while on treatment with Tarceva, except under the care of your HCP.
Smoking
Smoking may affect how well Tarceva works for you. If you smoke, you should stop smoking before starting treatment with Tarceva. Talk with your HCP about quitting smoking.
Common side effects of Tarceva
The most common side effects in patients who took Tarceva for non-small cell lung cancer (NSCLC) were mild to moderate rash and diarrhea. You may also have other changes in your skin.
The most common side effects in patients who took Tarceva plus gemcitabine for pancreatic cancer were fatigue "feeling tired", rash, nausea, loss of appetite and diarrhea.
The rash from Tarceva therapy may appear on your upper body or face. Typically rash occurs within 8-10 days of starting this treatment, but it may occur anytime during treatment with Tarceva.
The rash is not an allergic reaction. It may look like acne or dry skin. It is not acne. Talk to your HCP if a rash occurs.
Typically, diarrhea may develop within 12-15 days of starting Tarceva.
Hair and nail changes have been seen with Tarceva.
Always let your HCP know if you have any side effects, and ask about the best way to handle them.
Tarceva is not right for everyone. Ask your HCP if once-daily Tarceva is right for you.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1 (800) FDA-1088.
